Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 9/20 | 0.65 |
| ▸ | CYP4A11 | Q02928 | 9/20 | 0.65 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7490725 | 0.83 | CYP4F2 (0.55) | CYP4F2CYP4A11FFAR1HRH3 | |
| Hydrochloric Acid SCHEMBL7490717 | 0.82 | CYP4F2 (0.54) | CYP4F2CYP4A11FFAR1HRH3 | |
| SCHEMBL14457112 | 0.81 | CYP4F2 (0.60) | CYP4F2CYP4A11PPARGPPARA | |
| SCHEMBL22070572 | 0.81 | CYP4F2 (0.82) | CYP4F2CYP4A11PPARGPPARAFFAR1 | |
| SCHEMBL20730255 | 0.80 | CYP4F2 (0.79) | CYP4F2CYP4A11PPARGPPARAFFAR1 | |
| SCHEMBL23309219 | 0.79 | CYP4F2 (1.00) | CYP4F2CYP4A11PPARGPPARA | |
| SCHEMBL6861924 | 0.79 | CYP4F2 (0.57) | CYP4F2CYP4A11PPARGPPARA | |
| SCHEMBL338133 | 0.78 | CYP4F2 (0.51) | CYP4F2CYP4A11 | |
| SCHEMBL433940 | 0.75 | CYP4F2 (0.50) | CYP4F2CYP4A11PPARGPPARA | |
| SCHEMBL846867 | 0.74 | CTSB (0.58) | CYP4F2CYP4A11PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6797714-B2 | HYPOGLYCEMIC AGENTS; ANTIDIABETIC AGENTS; SIDE EFFECT REDUCTION | BAYER PHARMACEUTICALS CORPORATION | 2004-09-28 | — | — | US | disclosed |
| US-20030013705-A1 | Novel carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists | BAYER PHARMACEUTICALS CORPORATION | 2003-01-16 | — | — | US | disclosed |
| US-6469031-B1 | USEFUL IN THE TREATMENT OF CONDITIONS SUCH AS HYPER-TRIGLYCERIDAEMIA, HYPERCHOLESTEROLAEMIA AND IN LOWERING HIGH DENSITY LIPOPROTEIN LEVELS AS WELL AS IN THE TREATMENT OF ATHEROSCLEROTIC, CARDIOVASCULAR AND DIABETIC CONDITIONS | BAYER CORPORATION | 2002-10-22 | — | — | US | disclosed |
| EP-1040106-B1 | CARBOXYL SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA 3 ADRENORECEPTOR AGONISTS | BAYER AG (US) | 2002-08-28 | — | — | EP | disclosed |
| CN-1284952-A | Carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists | BAYER AG (US) | 2001-02-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013705-A1 | Novel carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists | ADRB3, ADRB1, ADRB2 | CYP4F2 1328/4885CYP4A11 301/4885PPARG 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.